Compare Eli Lilly And Co (LLY) vs Under Armour Inc Class A (UAA) Price & Performance

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Under Armour (UAA) is trading at $5.265, down 10.15% with bearish technical signals despite recent earnings beats. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent Q1 2027 earnings showed a profit beat but weaker revenue and cautious guidance, reflecting ongoing struggles in North American and Asia-Pacific markets. Cash flow remains negative at -$362M for 2025, though valuation ratios like P/S of 0.46 appear attractive relative to peers.

The outlook remains challenging with persistent revenue declines and profitability issues offset by potential value opportunities. Key risks include weak consumer spending, inventory management challenges, and competitive pressures. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels, though institutional sentiment appears cautious given the technical bearish signals and fundamental headwinds.